Protagonist Therapeutics Inc (NASDAQ: PTGX) is 81.64% higher on its value in year-to-date trading and has touched a low of $16.80 and a high of $48.89 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The PTGX stock was last observed hovering at around $40.65 in the last trading session, with the day’s gains setting it 1.0%.
Currently trading at $41.65, the stock is -6.83% and -7.98% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 0.94 million and changing 2.46% at the moment leaves the stock 16.38% off its SMA200. PTGX registered 139.92% gain for a year compared to 6-month gain of 36.38%. The firm has a 50-day simple moving average (SMA 50) of $45.3426 and a 200-day simple moving average (SMA200) of $35.7066.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -10.60% loss in the last 1 month and extending the period to 3 months gives it a -0.07%, and is 1.49% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 8.92% over the week and 5.45% over the month.
Protagonist Therapeutics Inc (PTGX) has around 112 employees, a market worth around $2.48B and $323.80M in sales. Current P/E ratio is 15.63. Profit margin for the company is 52.76%. Distance from 52-week low is 147.92% and -14.81% from its 52-week high. The company has generated returns on investments over the last 12 months (31.48%).
The EPS is expected to grow by 277.70% this year
332.0 institutions hold shares in Protagonist Therapeutics Inc (PTGX), with institutional investors hold 108.23% of the company’s shares. The shares outstanding are 57.71M, and float is at 56.31M with Short Float at 5.83%. Institutions hold 106.96% of the Float.
The top institutional shareholder in the company is FARALLON CAPITAL MANAGEMENT LLC with over 5.84 million shares valued at $202.38 million. The investor’s holdings represent 9.5274 of the PTGX Shares outstanding. As of 2024-06-30, the second largest holder is BLACKROCK INC. with 5.76 million shares valued at $199.52 million to account for 9.3925 of the shares outstanding. The other top investors are RTW INVESTMENTS, LP which holds 5.29 million shares representing 8.6231 and valued at over $183.17 million, while BVF INC/IL holds 5.4144 of the shares totaling 3.32 million with a market value of $115.01 million.
Protagonist Therapeutics Inc (PTGX) Insider Activity
The most recent transaction is an insider sale by MOLINA ARTURO MD, the company’s Chief Medical Officer. SEC filings show that MOLINA ARTURO MD sold 1,906 shares of the company’s common stock on Nov 15 ’24 at a price of $40.98 per share for a total of $78108.0. Following the sale, the insider now owns 46444.0 shares.
Protagonist Therapeutics Inc disclosed in a document filed with the SEC on Sep 11 ’24 that Ali Asif (Chief Financial Officer) sold a total of 14,203 shares of the company’s common stock. The trade occurred on Sep 11 ’24 and was made at $44.49 per share for $0.63 million. Following the transaction, the insider now directly holds 34960.0 shares of the PTGX stock.
Still, SEC filings show that on Sep 10 ’24, Waddill William D. (Director) disposed off 8,000 shares at an average price of $45.00 for $0.36 million. The insider now directly holds 12,000 shares of Protagonist Therapeutics Inc (PTGX).
